Duffy-null and chemotherapy dosing for solid tumors
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how a common genetic trait (Duffy-null) affects white blood cell counts and how that might change the dose of chemotherapy that is safe for you. If you have Middle Eastern or African ancestry and are about to start chemo for a solid tumor, this trial may help your doctor choose the right dose from the start.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be of Middle Eastern or African descent.
- You must have a solid tumor cancer (not sarcoma) that hasn't been treated yet, except maybe surgery.
- You must be between 18 and 80 years old.
- You must not have an active infection that needs IV antibiotics, unless it's under control.
- You must not be pregnant or breastfeeding, and you must be willing to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
This trial checks if adjusting the dose of chemotherapy drugs 5-FU or capecitabine based on your DPYD genetic results can improve safety and effectiveness. It’s for people with cancer who are about to start these drugs for the first time.
This Phase 2 study tests whether you can treat early-stage Hodgkin lymphoma with chemotherapy while avoiding radiation. It may help reduce radiation-related side effects if the treatment controls the cancer effectively.
This trial tests a new drug, DXC006, for people with advanced solid tumors or blood cancers like multiple myeloma and neuroblastoma that have not responded to standard treatments. The goal is to see if it is safe and effective.
This trial studies whether a blood test (ctDNA) can help doctors safely reduce chemotherapy for people with advanced Hodgkin lymphoma. If you have stage 3 or 4 Hodgkin lymphoma that hasn't been treated yet and are healthy enough for strong chemo, this study may be an option for you.
This study tests whether starting with a lower dose of chemotherapy works as well as the standard dose for people aged 70 and older with metastatic colorectal cancer. The goal is to find a treatment that is effective but gentler, with fewer side effects.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.